Objective: The Anaconda stent graft device presents peculiar and unique features in its design and deployment sequence, available on the market for many years with minor modifications, among different generations. The aim of this study was to assess the long-term, real-life, outcomes obtained in two high-volume centers with this endograft for infrarenal aortic aneurysms treatment over a period of 19 years.
Methods: All patients treated with the investigated device between 2000 and 2019, with at least 1 year of follow-up, were entered into a prospective database and data were reviewed retrospectively. The long-term results were assessed according to the Kaplan-Meier method. Primary outcomes were overall survival, freedom from AAA rupture, and freedom from AAA-related death. Secondary outcomes were freedom from late reintervention, freedom from late conversion to open repair, freedom from late limb occlusion, and freedom from late EVAR failure.
Results: A total of 260 consecutive patients were treated during the study period. Technical success was achieved in 98.5% (256/260) of the cases. Two perioperative deaths (0.8%) and four major complications (1.5%) were recorded. At a mean follow-up of 54 ± 38 months (summary follow-up index = 0.86), the late survival estimate was 94.8% at 1 year, 75.2% at 5 years, 50.5% at 10 years, and 43.3% at 13 years, with no case of late AAA rupture or late AAA-related death. Late freedom from conversion was 99.2% at 1 year, 96.9% at 5 years, 94.0% at 10 years, and 94.0% at 13 years. Freedom from late limb thrombosis was 96.8% at 1 year and 91.0% at 5, 10, and 13 years. Estimates of freedom from late reintervention was 95.6% at 1 year, 87.0% at 5 years, 77.4% at 10 years, and 77.4% at 13 years. Estimates of limb thrombosis at 11 years were significantly different in patients receiving or not intraoperative iliac kissing balloon maneuver with noncompliant angioplasty catheters (98.0% vs 88.4%; P = .029).
Conclusions: The Anaconda stent graft demonstrated effective and durable outcomes for AAA treatment over a 19-year period, with no case of late AAA rupture or AAA related death in the studied population. Late limb occlusion was the leading cause of reintervention; however, a positive prevention strategy was found in intraoperative kissing balloon, which was associated with significant reduced rate of iliac thrombosis over time.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jvs.2020.12.060 | DOI Listing |
Ann Thorac Surg Short Rep
December 2024
Institute for Integrated Life Skills, LLC, Bermuda Run, North Carolina.
Background: The expanded polytetrafluoroethylene (ePTFE) valved conduit (VC) has been reported for pulmonary valve replacement (PVR). The purpose of this study was to review long-term outcomes of our trileaflet ePTFE VC.
Methods: This multicenter study was performed with institutional review board approval from each institution.
Ann Thorac Surg Short Rep
June 2024
University Department of Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany.
Background: Comparative studies of outcomes between different biological mitral valve prostheses are scarce. This study compares the late clinical results of valve replacement with the Epic and Mosaic bioprostheses.
Methods: Patients undergoing isolated elective mitral valve replacement (MVR) between 2005 and 2019 were eligible for inclusion.
Eur J Heart Fail
January 2025
Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, USA.
Aims: As patients experience longer survival on HeartMate 3 left ventricular assist devices, there is a need to characterize long-term risks of adverse outcomes more precisely. This study characterized temporal variations in risks of mortality and adverse outcomes in patients with a HeartMate 3.
Methods And Results: From October 2015 to January 2023, 431 HeartMate 3 devices were implanted at Cleveland Clinic.
Thorac Cardiovasc Surg
January 2025
Cardiothoracic surgery, CHU de Rennes, Rennes, France.
Background: The long-term comparative results between porcine and pericardial bioprostheses for surgical aortic valve replacement (SAVR) is debated. Scarce information exists concerning direct comparative evaluation among contemporary devices. We compared late and very late results in a single center series (N=3,983 cases).
View Article and Find Full Text PDFStrahlenther Onkol
January 2025
Klinik für Strahlentherapie und Radioonkologie, Universitätsmedizin Göttingen, Robert-Koch-Straße 40, 37075, Göttingen, Germany.
Purpose: Neoadjuvant radiochemotherapy (NARCT) is an established standard of care in various tumor entities, promoting high response rates at commonly lower toxicities as compared to adjuvant approaches. This retrospective analysis was designed to investigate NARCT in early-stage high-risk cervical cancer.
Methods: Forty patients with early-stage high-risk cervical cancer (i.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!